What is Cytomos?
Cytomos is at the forefront of cell analysis technology, offering proprietary systems like AuraCyt® and Celledonia. These solutions are designed to overcome traditional bioprocessing bottlenecks by delivering rapid, data-rich insights crucial for cell line development and bioprocess optimization. The company primarily serves clients in the monoclonal antibody, viral vector production, and cell therapy sectors, aiming to reduce development costs and accelerate time-to-market. Their focus on enhancing bioprocessing efficiency positions them as a key player in the biotechnology and pharmaceutical industries.
How much funding has Cytomos raised?
Cytomos has raised a total of $13.3M across 3 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$5M
Other Financing Round
$6.3M
Angel/Seed (2022): $2M with participation from Scottish Enterprise and Old College Capital
Other Financing Round (2023): $5M led by Old College Capital, British Business Bank, Scottish Enterprise, and Archangels
Other Financing Round (2024): $6.4M supported by British Business Bank, Archangel Capital Partners, Edinburgh Innovations, and Scottish Enterprise
Key Investors in Cytomos
British Business Bank
The British Business Bank is a UK government-owned entity focused on increasing the supply of credit and business advice to small and medium-sized enterprises, indicating a strategic interest in supporting scalable ventures.
Archangel Capital Partners
Archangel Capital Partners, with a background in developing senior living communities, may be diversifying its investment portfolio or sees a unique long-term value proposition in Cytomos's technology.
Edinburgh Innovations
Edinburgh Innovations, the University of Edinburgh's industry engagement arm, typically invests in ventures that leverage university research, suggesting Cytomos may have strong ties to academic innovation in cell analysis.
What's next for Cytomos?
With its recent major strategic investment, Cytomos is poised for significant expansion and further development of its advanced cell analysis technologies. This capital injection is expected to fuel innovation, enhance market penetration, and potentially scale up operations to meet the growing demand for efficient bioprocessing solutions. The company's strategic focus on accelerating time-to-market for critical therapies suggests a future geared towards solidifying its position as a leader in the biopharmaceutical R&D and manufacturing support sector.
See full Cytomos company page
